Profiling of hepatocellular carcinoma cell cycle regulating genes targeted by calycosin.
We cocultured calycosin with human hepatocellular carcinoma cell line (BEL-7402) to investigate the effect on cell proliferation. Calycosin can markedly block the cell growth in G1 phase (P < 0.01) on the IC50 concentration. There were seventeen genes involved in cell-cycle regulation showing differentially expressed in treated cells detected by gene chip. Eight genes were upregulated and nine genes were downregulated. Downregulated TFDP-1, CDKN2D, and SPK2 and upregulated CDC2 and CCNB1 might affect cell cycle of tumor cells. Furthermore, we checked the transcription pattern using 2D gel method to find different expression of proteins in human hepatocellular carcinoma cells after exposure to calycosin. Fourteen proteins were identified by matrix-assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS). Twelve proteins expression were increased such as transgelin 2, pyridoxine 5'-phosphate, stress-induced-phosphoprotein 1, peroxiredoxin 1, endoplasmic reticulum protein 29, and phosphoglycerate mutase 1. Only thioredoxin peroxidase and high-mobility group box1 proteins' expression decreased. Both genes and proteins changes might be relate to the mechanism of antitumor effect under treatment of calycosin. In conclusion, calycosin has a potential effect to inhibit the BEL-7402 cell growth by inhibiting some oncogene expression and increasing anticancer genes expression, what is more, by blocking cell cycle.
Department of Blood Transfusion, General Hospital of PLA, Beijing 100853, China.
Dongqing
D
Zhang
Department of Blood Transfusion, General Hospital of PLA, Beijing 100853, China.
Shufang
S
Wang
Department of Blood Transfusion, General Hospital of PLA, Beijing 100853, China.
Liguo
L
Zhu
Department of Blood Transfusion, General Hospital of PLA, Beijing 100853, China.
Yaping
Y
Tian
Department of Blood Transfusion, General Hospital of PLA, Beijing 100853, China.
Haibao
H
Wang
Department of Blood Transfusion, General Hospital of PLA, Beijing 100853, China.
Yuan
Y
Zhuang
Department of Toxicology, Beijing Center for Diseases Control and Prevention, Beijing 100013, China.
Yu
Y
Li
Department of Blood Transfusion, General Hospital of PLA, Beijing 100853, China.
Deqing
D
Wang
D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000235:genetics*; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics; D018797:Cell Cycle Proteins / Q000096:biosynthesis*; D049109:Cell Proliferation / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D040901:Proteomics; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D018797:Cell Cycle Proteins; D007529:Isoflavones; C121707:7,3'-dihydroxy-4'-methoxyisoflavone